SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Research and Development Expense
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Research and Development Expense of $55.66 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $55.66K, a 94.57% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $267.24K, a 83.02% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $511.88K, a 48.11% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $943.48K, a 32.64% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. research and development expense for fiscal 2025 was $4.05M, a 12.05% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. research and development expense for fiscal 2024 was $3.62M, a 2.89% increase from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. research and development expense for fiscal 2023 was $3.52M, a 235.80% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. research and development expense for fiscal 2022 was $1.05M, a 2.50% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $55.66K 10-Q · filed 2026-09-24 | $322.90K 10-Q · filed 2026-09-24 | $834.78K derived: sum of 3 quarters · filed 2026-09-24 | $1.78M derived: sum of 4 quarters · filed 2026-09-24 | ||||
| 2026-03-31 | $267.24K 10-Q · filed 2026-05-15 | $779.12K derived: sum of 2 quarters · filed 2026-05-15 | $1.72M derived: sum of 3 quarters · filed 2026-05-15 | $2.75M derived: sum of 4 quarters · filed 2026-09-24 | ||||
| 2025-12-31 | $511.88K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.46M derived: sum of 2 quarters · filed 2026-03-31 | $2.48M derived: sum of 3 quarters · filed 2026-09-24 | $4.05M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $943.48K 10-Q · filed 2025-11-13 | $1.97M derived: sum of 2 quarters · filed 2026-09-24 | $3.54M 10-Q · filed 2025-11-13 | $4.53M derived: sum of 4 quarters · filed 2026-09-24 | ||||
| 2025-06-30 | $1.03M 10-Q · filed 2026-09-24 | $2.60M 10-Q · filed 2026-09-24 | $3.59M derived: sum of 3 quarters · filed 2026-09-24 | $4.99M derived: sum of 4 quarters · filed 2026-09-24 | ||||
| 2025-03-31 | $1.57M 10-Q · filed 2026-05-15 | $2.56M derived: sum of 2 quarters · filed 2026-05-15 | $3.96M derived: sum of 3 quarters · filed 2026-05-15 | $4.61M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $986.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.39M derived: sum of 2 quarters · filed 2026-03-31 | $3.03M derived: sum of 3 quarters · filed 2026-03-31 | $3.62M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $1.40M 10-Q · filed 2025-11-13 | $2.05M derived: sum of 2 quarters · filed 2025-11-13 | $2.63M 10-Q · filed 2025-11-13 | $3.34M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $645.72K 10-Q · filed 2025-08-13 | $1.23M 10-Q · filed 2025-08-13 | $1.94M derived: sum of 3 quarters · filed 2025-08-13 | $2.99M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $586.10K 10-Q · filed 2025-05-08 | $1.30M derived: sum of 2 quarters · filed 2025-05-08 | $2.34M derived: sum of 3 quarters · filed 2025-05-08 | $3.18M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $710.45K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.76M derived: sum of 2 quarters · filed 2025-02-26 | $2.60M derived: sum of 3 quarters · filed 2025-02-26 | $3.52M 10-K · filed 2025-02-26 | ||||
| 2023-09-30 | $1.05M 10-Q · filed 2024-11-13 | $1.14M 10-Q · filed 2023-11-13 | $1.88M derived: sum of 2 quarters · filed 2024-11-13 | $2.81M 10-Q · filed 2024-11-13 | $3.08M 10-Q · filed 2023-11-13 | $2.81M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $839.66K 10-Q · filed 2024-09-04 | $933.37K 10-Q · filed 2023-08-14 | $1.76M 10-Q · filed 2024-09-04 | $1.94M 10-Q · filed 2023-08-14 | $1.76M derived: sum of 3 quarters · filed 2024-09-04 | $2.43M derived: sum of 4 quarters · filed 2024-09-04 | ||
| 2023-03-31 | $921.80K 10-Q/A · filed 2024-09-04 | $1.01M 10-Q · filed 2023-05-25 | $920.37K derived: sum of 2 quarters · filed 2024-09-04 | $1.59M derived: sum of 3 quarters · filed 2024-09-04 | $1.67M derived: sum of 4 quarters · filed 2024-09-04 | |||
| 2022-12-31 | -$1.44K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $667.60K derived: sum of 2 quarters · filed 2024-09-04 | $751.47K derived: sum of 3 quarters · filed 2024-09-04 | $1.05M 10-K/A · filed 2024-09-04 | $1.49M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $669.04K 10-Q · filed 2023-11-13 | $752.91K derived: sum of 2 quarters · filed 2023-11-13 | $1.05M 10-Q · filed 2023-11-13 | $1.49M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $83.87K 10-Q · filed 2023-08-14 | $379.78K 10-Q · filed 2023-08-14 | $821.91K derived: sum of 3 quarters · filed 2023-08-14 | $1.01M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $295.92K 10-Q · filed 2023-05-25 | $738.04K derived: sum of 2 quarters · filed 2023-05-25 | $925.00K derived: sum of 3 quarters · filed 2023-05-25 | |||||
| 2021-12-31 | $442.12K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $629.08K derived: sum of 2 quarters · filed 2023-03-15 | $1.02M 10-K · filed 2023-03-15 | |||||
| 2021-09-30 | $186.96K 10-Q · filed 2022-11-14 | $579.68K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |